| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/17/2003 | EP1343496A1 Anticancer agent comprising mycolactone |
| 09/17/2003 | EP1343495A2 Methods of treating anxiety disorders |
| 09/17/2003 | EP1343493A2 Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| 09/17/2003 | EP1343492A2 Treatment of mucositis |
| 09/17/2003 | EP1343491A2 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 09/17/2003 | EP1343490A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof |
| 09/17/2003 | EP1343488A1 Treatment of statin side effects |
| 09/17/2003 | EP1343487A2 Methods and compositions to treat conditions associated with neovascularization |
| 09/17/2003 | EP1343486A1 Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration |
| 09/17/2003 | EP1343485A2 Lipid-based nitric oxide donors |
| 09/17/2003 | EP1343484A2 Transdermal systems (tds) that contain inhibitors of phosphodiesterase iv |
| 09/17/2003 | EP1343483A2 Transdermal system containing a novel high potency progestagen |
| 09/17/2003 | EP1343480A2 Induced phase transition method for the production of microparticles containing hydrophobic active agents |
| 09/17/2003 | EP1343479A2 Aerogel powder therapeutic agents |
| 09/17/2003 | EP1343478A2 Induced phase transition method for the production of microparticles containing hydrophilic active agents |
| 09/17/2003 | EP1343477A2 Treatment of inoperable tumors by stereotactic injection of microspheres |
| 09/17/2003 | EP1343475A2 Self forming, thermodynamically stable liposomes and their applications |
| 09/17/2003 | EP1343473A1 Pharmaceutical dronedarone composition for parenteral administration |
| 09/17/2003 | EP1343467A1 Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least a carotenoid |
| 09/17/2003 | EP1343465A2 Use of dna repair enzymes as mmp-1 inhibitors |
| 09/17/2003 | EP1343462A2 Antiperspirant products |
| 09/17/2003 | EP1343459A1 Composition, in particular cosmetic, containing 7-hydroxy dhea and/or 7-keto dhea and at least one isoflavonoid |
| 09/17/2003 | EP1343434A1 Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| 09/17/2003 | EP1343390A2 Materials and methods for the treatment or prevention of obesity |
| 09/17/2003 | EP1343372A2 Pulmonary delivery of polyene antifungal agents |
| 09/17/2003 | EP1314426A9 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 09/17/2003 | EP1282622B1 Crf receptor antagonists and methods relating thereto |
| 09/17/2003 | EP1282084B1 Method for preparing pyrimidone derivatives with antifungal activity |
| 09/17/2003 | EP1244452B1 Carboxamide derivates of pyrrolidine and piperidine as urotensin-ii receptor antagonists |
| 09/17/2003 | EP1230230B1 Indeno-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 09/17/2003 | EP1224174B1 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 09/17/2003 | EP1224166B1 Method of producing n-(4,5-bis-methanesulfonyl-2-methyl-benzoyl)-guanidine, the hydrochloride thereof |
| 09/17/2003 | EP1207875B1 Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| 09/17/2003 | EP1200445B1 Thienopyranecarboxamide derivatives |
| 09/17/2003 | EP1196411B1 Bradykinin b1 receptor antagonists |
| 09/17/2003 | EP1192163B1 DITHIEPINO 6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 09/17/2003 | EP1183241B1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 09/17/2003 | EP1181300B1 6-o-carbamate ketolide derivatives |
| 09/17/2003 | EP1159295B1 Method of purifying whey of lactic acid fermentation by electrodialysis |
| 09/17/2003 | EP1150662B1 Laminates containing an active substance for transdermal systems |
| 09/17/2003 | EP1150655B1 Use of nanoscale chitosanes |
| 09/17/2003 | EP1147119B1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors |
| 09/17/2003 | EP1143966B1 Preparation for warts |
| 09/17/2003 | EP1133471B1 Hydrazine derivatives |
| 09/17/2003 | EP1123296B1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| 09/17/2003 | EP1117394B1 Use of carnitines and resveratrol to produce a composition for the prevention or therapeutic treatment of cerebral disorders brought about by ageing and use of neurotoxic drugs |
| 09/17/2003 | EP1105132B1 The use of r(+)-g(a)-(2,3-dimethoxyphenyl)-1- 2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of obstructive sleep apnea |
| 09/17/2003 | EP1100471B1 Compressed compositions comprising clarified xanthan gum |
| 09/17/2003 | EP1095021B1 Quinoline derivatives |
| 09/17/2003 | EP1091734B1 Method for reducing the damaging effects of radiation therapy on animal skin and mucosa |
| 09/17/2003 | EP1079828B1 Compositions comprising 5-hydroxyindole as a modulator of a nicotinic receptor |
| 09/17/2003 | EP1058548B1 The use of isatin and oxindole derivatives in the preparation of a medicament for use in the treatment of mycobacterial disease |
| 09/17/2003 | EP1049697B1 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 09/17/2003 | EP1049672B1 Azetidinecarboxamide derivatives for treating cns disorders |
| 09/17/2003 | EP1042327B1 A process for the reduction of oxiranyl epothilones to olefinic epothilones |
| 09/17/2003 | EP1033973B1 Encapsulation method |
| 09/17/2003 | EP1030852B1 Oxazolidinone derivatives and pharmaceutical compositions |
| 09/17/2003 | EP1027359B9 Monocyclic l-nucleosides, analogs and uses thereof |
| 09/17/2003 | EP1023267B1 Pyridyl compounds and pharmaceutical compositions containing them |
| 09/17/2003 | EP1009755B1 Steroid sulfatase inhibitors and methods for making and using the same |
| 09/17/2003 | EP0996446B1 Novel substituted imidazole compounds |
| 09/17/2003 | EP0984777B1 Arylsubstituted piperazines useful in the treatement of benign prostatic hyperlasia |
| 09/17/2003 | EP0977737B1 Crf antagonistic quino- and quinazolines |
| 09/17/2003 | EP0975325B1 Compositions comprising a combination of a free sphingoid base and a ceramide and use thereof |
| 09/17/2003 | EP0950051B1 Micro-particulate form of a tetrahydropyridin derivative |
| 09/17/2003 | EP0946179B1 Use of olanzapine or a pharmaceutically acceptable salt for the manufacture of a medicament for the treatment of autism and mental retardation |
| 09/17/2003 | EP0941099B1 Treatment of bronchitis with diuridine tetraphosphate |
| 09/17/2003 | EP0925068B1 Use of a pharmaceutical composition containing polyphenols from grapes or from wine, in particular resveratrol, and yeast extracts |
| 09/17/2003 | EP0914114B1 Methods of treating type i hypersensitivity using monophosphoryl lipid a |
| 09/17/2003 | EP0910566B1 Heterocyclic compounds and their preparation and use |
| 09/17/2003 | EP0909184B1 Targeted drug delivery using sulfonamide derivatives |
| 09/17/2003 | EP0891329B1 Peptidyl compounds having mmp and tnf inhibitory activity |
| 09/17/2003 | EP0874623B1 Water activatable adhesive matrix containing amethocaine |
| 09/17/2003 | EP0831937B1 Immunological combination compositions and methods |
| 09/17/2003 | EP0804439B1 Beta, beta '-dihydroxy meso-substituted chlorins, isobacteriochlorins, bacteriochlorins, and methods for making the same from beta ,beta '-unsubstituted tetrapyrrolic macrocycles |
| 09/17/2003 | EP0769940B1 INDENE sPLA2 INHIBITORS |
| 09/17/2003 | EP0766960B1 External preparations for treating dermatoses |
| 09/17/2003 | EP0754682B9 Aminostilbazole derivative and medicine |
| 09/17/2003 | EP0724647A4 Nucleic acid ligands and improved methods for producing the same |
| 09/17/2003 | EP0702683B1 06-substituted guanine derivatives, a process for their preparation and their use in treating tumour cells |
| 09/17/2003 | EP0668762B1 Isobutenyl-substituted taxanes and their pharmaceutical compositions |
| 09/17/2003 | EP0588858B1 IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE |
| 09/17/2003 | CN1443239A Compositions and methods for therapy and diagnosis of breast cancer |
| 09/17/2003 | CN1443197A Acid-modified arabinogalactan protein composition |
| 09/17/2003 | CN1443196A Protein complex serving as vehicle for orally administerable medicaments |
| 09/17/2003 | CN1443192A Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| 09/17/2003 | CN1443191A Methods and compositions for treating hepatitis c virus |
| 09/17/2003 | CN1443190A Matrix metalloproteinase inhibitors |
| 09/17/2003 | CN1443189A Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 09/17/2003 | CN1443188A Process for preparation of 9-amino substituted 9,10-dihydropyrrolo [2,1-b] [1,3] benzotiazepines |
| 09/17/2003 | CN1443187A Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 09/17/2003 | CN1443186A Thiazolidinedione salt for treatment of diabetes mellitus |
| 09/17/2003 | CN1443185A 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2, 4-dione hydriodide as pharmaceutical |
| 09/17/2003 | CN1443184A 嘧啶衍生物 Pyrimidine derivatives |
| 09/17/2003 | CN1443179A Aniline derivatives |
| 09/17/2003 | CN1443178A (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl] -4-morpholibenzamide |
| 09/17/2003 | CN1443177A Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| 09/17/2003 | CN1443176A Valsartan salts |
| 09/17/2003 | CN1443174A Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines |
| 09/17/2003 | CN1443173A Substituted imidazoles as TAFI a inhibitors |